Astrazeneca Says Tozorakimab Significantly Lowers COPD in Phase 3 Study

MT Newswires Live04-20

AstraZeneca (AZN) said Monday its pivotal phase 3 study of tozorakimab demonstrated a "significant" reduction in the annual rate of moderate-to-severe chronic obstructive pulmonary disease, or COPD, exacerbations in trial participants.

The population comprised former smokers, current smokers and participants throughout all blood eosinophil counts and all stages of lung function severity, according to the company.

AstraZeneca said participants were given 300mg tozorakimab or a placebo on top of standard of care once bi-weekly, adding that it admitted participants with COPD still experiencing moderate-to-severe exacerbations during inhaled standard of care.

Tozorakimab was "generally well tolerated" and had a "favorable safety profile" consistent with prior findings, the company said. It is also being evaluated in a phase 3 study for severe viral lower respiratory tract disease and in a phase 2 asthma study.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment